NLS Pharmaceutics Ltd (NASDAQ: NLSP) stock jumped 9.38% on Friday to $0.35 against a previous-day closing price of $0.32. With 0.29 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.13 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.3800 whereas the lowest price it dropped to was $0.3200. The 52-week range on NLSP shows that it touched its highest point at $1.88 and its lowest point at $0.26 during that stretch. It currently has a 1-year price target of $4.00. Beta for the stock currently stands at -0.92.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NLSP was down-trending over the past week, with a drop of -45.30%, but this was down by -53.79% over a month. Three-month performance dropped to -57.32% while six-month performance fell -69.30%. The stock lost -31.75% in the past year, while it has lost -72.87% so far this year. A look at the trailing 12-month EPS for NLSP yields -0.84 with Next year EPS estimates of -0.45.
Float and Shares Shorts:
At present, 32.43 million NLSP shares are outstanding with a float of 19.95 million shares on hand for trading. On Oct 30, 2023, short shares totaled 0.17 million, which was 0.51% higher than short shares on Sep 28, 2023. In addition to Mr. Alexander Zwyer M.B.A. as the firm’s President, CEO & Director, Dr. George Apostol M.D. serves as its Chief Medical Officer and Global Head of Research & Development.
Through their ownership of 19.94% of NLSP’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 28.76% of NLSP, in contrast to 0.35% held by mutual funds. As the largest shareholder in NLSP with 17.72% of the stake, BVF Partners LP holds 5,747,126 shares worth 5,747,126. A second-largest stockholder of NLSP, Yorkville Advisors Global LP, holds 3,047,011 shares, controlling over 9.40% of the firm’s shares. J. Goldman & Co. LP is the third largest shareholder in NLSP, holding 254,601 shares or 0.79% stake. With a 0.31% stake in NLSP, the SFR Global Wealth Fund is the largest stakeholder. A total of 100,000 shares are owned by the mutual fund manager. The Fidelity Nasdaq Composite Index F, which owns about 0.04% of NLSP stock, is the second-largest Mutual Fund holder. It holds 14,362 shares valued at 9479.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NLSP since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With NLSP analysts setting a high price target of $4.00 and a low target of $4.00, the average target price over the next 12 months is $4.00. Based on these targets, NLSP could surge 1042.86% to reach the target high and rise by 1042.86% to reach the target low. Reaching the average price target will result in a growth of 1042.86% from current levels.